Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Effects of a Tissue Selective Estrogen Complex (TESC) on Depression and the Neural Reward System in the Perimenopause

Trial Profile

Effects of a Tissue Selective Estrogen Complex (TESC) on Depression and the Neural Reward System in the Perimenopause

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 14 Jan 2019

At a glance

  • Drugs Conjugated estrogens/bazedoxifene (Primary)
  • Indications Major depressive disorder; Perimenopause
  • Focus Pharmacodynamics
  • Most Recent Events

    • 17 Dec 2018 Planned End Date changed from 1 Nov 2020 to 1 Dec 2020.
    • 17 Dec 2018 Planned primary completion date changed from 1 Nov 2020 to 1 Dec 2020.
    • 17 Dec 2018 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top